Fetroja (cefiderocol) / Shionogi - LARVOL DELTA

Cefiderocol-resistant Aeromonas with expanded Resistomes in German hospital wastewater: Phenotypic and genomic evidence from the environment-clinical Interface. (PubMed, Sci Total Environ) - "Resistance phenotypes diverged markedly: cefiderocol-selected wastewater isolates exhibited high resistance rates to multiple clinically relevant agents - ciprofloxacin (93.1%), aztreonam (81.2%), and trimethoprim-sulfamethoxazole (38.9%), whereas clinical isolates remained largely susceptible overall (<10%). Notably, extensive plasmid-backbone homology was detected between Aeromonas and co-occurring cefiderocol-resistant Enterobacterales isolated from the same wastewater samples, highlighting interspecies gene flow at the hospital-environment interface. Together, these findings identify hospital wastewater as a reservoir and convergence point for highly resistant, mobilome-enriched Aeromonas subpopulations captured under cefiderocol selection, supporting Aeromonas as a One Health sentinel and emphasizing the value of wastewater-based surveillance for tracking mobile resistance determinants bridging environmental and clinical compartments."

Journal • Gene Therapies • Infectious Disease

Evaluation of the In Vitro Activity of Cefiderocol Against Carbapenem-Resistant Enterobacterales Isolates (PubMed, Mikrobiyol Bul) - "This study aimed to evaluate the in vitro activity of cefiderocol, the concordance of susceptibility tests performed using three methods [broth microdilution (BMD) based commercial ComASP® panel , gradient strip and disk diffusion] and its association with major carbapenemase genes and the ceftazidime/avibactam (CZA) susceptibility. Cefiderocol demonstrated very high in vitro activity against CRE isolates and retained its activity against the majority of CZA-resistant strains. However, due to the risk of major errors-especially near breakpoint zones-disk diffusion results should be interpreted with caution, and confirmation with BMD is recommended in critical cases."

Journal • Preclinical • Infectious Disease

Assessment of cefiderocol susceptibility testing methods in Enterobacterales (ESCMID Global 2026) - No abstract available

Two Comprehensive Liquid Chromatography High-Resolution Mass Spectrometry (UPLC-MS/MS) Multi-Methods for Real-Time Therapeutic Drug Monitoring (TDM) of Five Novel Beta-Lactams and of Fosfomycin Administered by Continuous Infusion. (PubMed, Pharmaceutics) - " The aim of this study was to develop and validate two rapid, sensitive, and accurate UPLC-qTOF-MS/MS methods for the simultaneous quantification of five novel β-lactam or β-lactam/β-lactamase inhibitor combinations (ceftolozane/tazobactam, ceftazidime/avibactam, meropenem/vaborbactam, cefiderocol, and ceftobiprole) along with fosfomycin. These UPLC-qTOF-MS/MS multi-analyte methods enabled a simultaneous, reliable quantification in plasma of five novel beta-lactams and of fosfomycin. Robustness, high throughput, and sensitivity make these multi-methods feasible for real-time TDM, supporting personalized antimicrobial dosing and improved therapeutic outcomes in patients with severe or multidrug-resistant infections."

Journal • Infectious Disease

Activity of cefiderocol against non-fermenting Gram-negative isolates collected from intensive care unit patients in US and European medical centres as part of a SENTRY antimicrobial surveillance program (2020-2024) (ESCMID Global 2026) - No abstract available

Clinical • Gram negative • Critical care • Infectious Disease

Susceptibility to cefiderocol and other novel antibiotics against carbapenem-non-susceptible gram-negative bacilli. (PubMed, Jpn J Infect Dis) - "We conducted antimicrobial susceptibility testing on 89 clinical isolates of carbapenem-non-susceptible gram-negative bacilli (CNS-GNB) strains detected at our hospital, evaluating the efficacy of novel antibiotics including CFDC, ceftolozane/tazobactam, ceftazidime/avibactam, and imipenem/cilastatin/relebactam...Colistin were intermediate against all CPE and 92.5% of CRPA isolates. In S. maltophilia isolates, susceptibility to CFDC and trimethoprim-sulfamethoxazole were 100% and 89.3 %. Although non-susceptibility to CFDC appeared in 2 CRPA isolates, MIC90 of CFDC was within susceptible range against all three groups of clinical isolates. CFDC showed significant promise as a treatment option for infections caused by CNS-GNB."

Journal • Infectious Disease

Efficacy of cefiderocol and levofloxacin against Stenotrophomonas maltophilia in a hemorrhagic pneumonia mouse model. (PubMed, Antimicrob Agents Chemother) - "Treatment strategies that consider tissue penetration are necessary for severe S. maltophilia infections. However, the use of LVFX must consider the risk of resistance development, whereas CFDC may be advantageous for treating resistant pathogens."

Journal • Preclinical • Hematological Disorders • Infectious Disease • Pneumonia • Respiratory Diseases

Clinical use and effectiveness of cefiderocol in critically ill patients: a real-world ICU experience (ESCMID Global 2026) - No abstract available

Clinical • Real-world • Real-world evidence

Cefiderocol in clinical practice for bone and joint infections: insights from the PROVE study (ESCMID Global 2026) - No abstract available

Clinical • Infectious Disease

Cefiderocol treatment in polymicrobial infections: subgroup analysis of the real-world PROVE observational study (ESCMID Global 2026) - No abstract available

Clinical • Observational data • Real-world • Real-world evidence • Infectious Disease

CefiderocolFinder: detection of genomic adaptations implicated in cefiderocol resistance in 993 carbapenemase-producing organisms from the Netherlands, 2023-2024 (ESCMID Global 2026) - No abstract available

Population pharmacokinetic/pharmacodynamic analyses of cefiderocol for paediatric patients (ESCMID Global 2026) - No abstract available

Clinical • PK/PD data • Pediatrics

Does use of ceftazidime/avibactam increase the risk of in vivo emergence of ceftazidime/avibactam and cefiderocol cross-resistance in KPC-producing Klebsiella pneumoniae: a case-control study (ESCMID Global 2026) - No abstract available

Preclinical • Infectious Disease • Pneumonia

Cefiderocol as a decisive rescue therapy in Fournier's gangrene caused by extensively drug-resistant Pseudomonas aeruginosa after CAR-T therapy (ESCMID Global 2026) - No abstract available

A Case of Fatal Cupriavidus gilardii Sepsis Following Cord Blood Transplantation: Pitfalls of Novel Antimicrobial Agents. (PubMed, Int J Infect Dis) - "Cefiderocol (CFDC) is a novel antimicrobial agent that exhibits activity against carbapenem-resistant non-fermenting gram-negative bacilli, such as resistant Pseudomonas aeruginosa and Stenotrophomonas maltophilia, and has thus attracted considerable attention. Herein, we report a case in which a patient who was undergoing cord blood transplantation developed gram-negative rod sepsis after meropenem administration...The causative organism was later identified as Cupriavidus gilardii, which was resistant to novel antimicrobial agents, including CFDC, ceftazidime/avibactam, and ceftolozane/tazobactam. However, it was susceptible to cefepime and cefotaxime, suggesting a potential pitfall in the sole reliance on novel antibacterial drugs...This is the first reported case in the context of hematopoietic cell transplantation and the second diagnosed case using matrix-assisted laser desorption/ionization time-of-flight mass spectrometry. Moreover, this report presents a..."

Journal • Hematological Disorders • Infectious Disease • Neutropenia • Septic Shock • Transplantation

Genomic and phenotypic insights into cefiderocol resistance in Klebsiella pneumoniae (ESCMID Global 2026) - No abstract available

Infectious Disease • Pneumonia

IS12 - Exploring the role(s) of cefiderocol in optimising patient outcomes in CRGNI (ESCMID Global 2026) - "The symposium hopes to provide an overview of recent updates addressing some of the challenges of susceptibility testing for cefiderocol as well as sharing real world clinical experience of cefiderocol use in key critical priority pathogen. Experts will share their experiences, followed by a live panel discussion offering practical approaches to translate evidence into clinical decision-making."

Clinical • Infectious Disease

4990 - Emerging resistance to new antibiotics: are we already losing the newest tools? (ESCMID Global 2026) - "This session explores the troubling rise of resistance to recently approved antibiotics, including cefiderocol, ceftazidime-avibactam, imipenem/relebactam, cefepime-taniborbactam, aztreonam-avibactam, etc. Although these drugs were introduced as critical last-resort options against multidrug-resistant infections, reports of resistance have emerged within just a few years of clinical use. The panel will address the urgent need for improved stewardship, faster diagnostics, and equitable access to new antibiotics to preserve their effectiveness. Participants will gain insights into how resistance spreads, how policies impact antimicrobial use, and what strategies might still help us stay ahead in the race against resistant pathogens."

Infectious Disease

In vitro selection of cefiderocol-resistant mutants in Acinetobacter baumannii harboring the most common carbapenemase genes (ESCMID Global 2026) - No abstract available

Preclinical

Cefiderocol Use in Paediatric Intensive Care and Neonatal Intensive Care Units: Real-World Use, Safety, and Clinical Outcomes in a Tertiary Hospital (ESCMID Global 2026) - No abstract available

Clinical • Clinical data • Real-world • Real-world evidence • Critical care • Pediatrics

Cefiderocol retains potent activity against carbapenem-resistant Pseudomonas aeruginosa despite rare heteroresistance in Italy (ESCMID Global 2026) - No abstract available

In vitro evaluation of cefiderocol against Achromobacter xylosoxidans isolates from people with cystic fibrosis (ESCMID Global 2026) - No abstract available

Preclinical • Cystic Fibrosis • Genetic Disorders • Immunology • Respiratory Diseases

Cefiderocol demonstrated potent in vitro activity against carbapenem-resistant non-fermenting Gram-negative bacteria, including WHO priority pathogens, in China (ESCMID Global 2026) - No abstract available

Gram negative • Preclinical • Infectious Disease

Insights into Klebsiella pneumoniae carbapenem resistance-a two-year retrospective study from a Romanian tertiary care hospital. (PubMed, Front Microbiol) - "All carbapenem-non-susceptible Klebsiella pneumoniae strains (meropenem minimum inhibitory concentration > 0.125 μg/mL) further underwent extended-spectrum beta-lactamase (ESBL) and carbapenemase production testing via phenotypical methods...In terms of antimicrobial resistance, more than > 90% of the strains exhibited resistance to fluoroquinolones, third generation cephalosporins, penicillins and monobactams, > 75% resistance to aminoglycosides and novel beta-lactam/beta-lactamase inhibitor combinations and > 70% resistance to colistin and imipenem-relebactam. Overall cefiderocol resistance was 32.05%...Moreover, 54.17% (n = 104) of XDR isolates were only susceptible to one antimicrobial drug. Rates of resistance remain concerningly high amongst CRKP isolates, with double carbapenemase producers and XDR/PDR isolates dominating the landscape, implying the foreseeable need for updated means of approaching antimicrobial resistance, as last-resort..."

Journal • Retrospective data • Infectious Disease • Pneumonia

Molecular snapshot of cefiderocol non-susceptible Klebsiella pneumoniae from Greece (ESCMID Global 2026) - No abstract available

Infectious Disease • Pneumonia